Stockscreener 앱 받기
42.31
4.17%
-1.84
시간 외 거래:
42.03
-0.28
-0.66%
전일 마감가:
$44.15
열려 있는:
$44.53
하루 거래량:
1.46M
Relative Volume:
1.06
시가총액:
$3.98B
수익:
$4.72M
순이익/손실:
$-277.91M
주가수익비율:
-11.34
EPS:
-3.73
순현금흐름:
$-203.56M
1주 성능:
-7.54%
1개월 성능:
+24.08%
6개월 성능:
+43.04%
1년 성능:
-28.12%
1일 변동 폭
$41.68
$44.96
1주일 범위
$41.68
$46.05
52주 변동 폭
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
명칭
Crinetics Pharmaceuticals Inc
전화
858-450-6464
주소
6055 LUSK BLVD., SAN DIEGO, CA
CRNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
42.31 | 4.15B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 개시 | Goldman | Neutral |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-11 | 개시 | TD Cowen | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Peer Perform |
| 2025-01-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-01-16 | 개시 | Morgan Stanley | Overweight |
| 2023-12-21 | 개시 | Jefferies | Hold |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 개시 | Oppenheimer | Outperform |
| 2023-04-24 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Robert W. Baird | Outperform |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-23 | 개시 | Evercore ISI | Outperform |
| 2021-06-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 개시 | ROTH Capital | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2018-08-13 | 개시 | JP Morgan | Neutral |
| 2018-08-13 | 개시 | Leerink Partners | Outperform |
| 2018-08-13 | 개시 | Piper Jaffray | Overweight |
모두보기
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Hyperparathyroidism Pipeline 2025: Innovative Clinical Developments by 3+ Global Leaders – DelveInsight | Featuring Shanghai Hengrui Pharmaceutical, Shaanxi Micot Technology, Crinetics Pharmaceuticals - Barchart.com
Crinetics Pharmaceuticals Inc. stock outlook for YEAR2025 Trading Recap & Free Daily Entry Point Trade Alerts - newser.com
Will Crinetics Pharmaceuticals Inc. benefit from macro trends2025 Risk Factors & Consistent Growth Equity Picks - newser.com
Will Crinetics Pharmaceuticals Inc. stock keep outperforming rivals2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Is it time to cut losses on Crinetics Pharmaceuticals Inc.2025 Momentum Check & Smart Swing Trading Techniques - newser.com
Sector ETF performance correlation with Crinetics Pharmaceuticals Inc.Analyst Upgrade & Short-Term High Return Strategies - newser.com
Published on: 2025-10-15 10:15:16 - newser.com
Using data tools to time your Crinetics Pharmaceuticals Inc. exitRecession Risk & AI Forecast Swing Trade Picks - newser.com
What recovery options are there for Crinetics Pharmaceuticals Inc.Market Performance Summary & Fast Entry High Yield Stock Tips - newser.com
Crinetics Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Why Crinetics Pharmaceuticals (CRNX) Is Up 6.8% After FDA Approval of First Oral Acromegaly Therapy - Sahm
How to use a screener to detect Crinetics Pharmaceuticals Inc. breakouts2025 Technical Overview & Weekly Watchlist for Hot Stocks - newser.com
Published on: 2025-10-13 23:24:35 - newser.com
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
What candlestick patterns are forming on Crinetics Pharmaceuticals Inc.2025 Dividend Review & Free Community Consensus Stock Picks - newser.com
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Is it too late to sell Crinetics Pharmaceuticals Inc.Market Trend Summary & Verified Swing Trading Watchlists - newser.com
Crinetics Pharmaceuticals' (CRNX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Will a bounce in Crinetics Pharmaceuticals Inc. offer an exit2025 Market Outlook & Fast Momentum Stock Entry Tips - newser.com
Crinetics stock holds Overweight rating at Piper Sandler after acromegaly drug approval - Investing.com Canada
Crinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growth - Investing.com Nigeria
Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX) - Yahoo Finance
A Look at Crinetics Pharmaceuticals's Valuation Following FDA Approval of PALSONIFY for Acromegaly - Yahoo Finance
Crinetics Pharmaceuticals (CRNX): Assessing Valuation After a 15% Share Price Climb This Month - Sahm
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Using portfolio simulators with Crinetics Pharmaceuticals Inc. includedWeekly Stock Recap & Free Expert Verified Stock Movement Alerts - newser.com
What MACD and RSI say about Crinetics Pharmaceuticals Inc.Earnings Recap Report & Capital Efficient Trade Techniques - newser.com
Does Crinetics Pharmaceuticals Inc. fit your quant trading model2025 Support & Resistance & High Yield Stock Recommendations - newser.com
Comparing Crinetics Pharmaceuticals Inc. in custom built stock radarsMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crinetics Pharmaceuticals Shares Swing After Data on Paltusotine and Valuation Metrics Scrutinized - Sahm
Insider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Sells 5,000 Shares of Stock - MarketBeat
Crinetics Pharmaceuticals Hits Day High with 16.05% Surge in Stock Price - Markets Mojo
Crinetics Pharmaceuticals Inc (CRNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Crinetics Pharmaceuticals Inc 주식 (CRNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Oct 01 '25 |
Sale |
41.81 |
5,000 |
209,050 |
66,270 |
2.96%
0.09%
자본화:
|
볼륨(24시간):